APA (7th ed.) Citation

Tajiri, H., Motoya, S., Kinjo, F., Maemoto, A., Matsumoto, T., Sato, N., . . . Hibi, T. (2022). Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Tajiri, Hitoshi, et al. Correction: Infliximab for Pediatric Patients with Crohn’s Disease: A Phase 3, Open-label, Uncontrolled, Multicenter Trial in Japan. Public Library of Science (PLoS), 2022.

MLA (9th ed.) Citation

Tajiri, Hitoshi, et al. Correction: Infliximab for Pediatric Patients with Crohn’s Disease: A Phase 3, Open-label, Uncontrolled, Multicenter Trial in Japan. Public Library of Science (PLoS), 2022.

Warning: These citations may not always be 100% accurate.